Travere trips up but others are following in rare kidney disease

Travere’s attempt to win accelerated approval for Filspari in focal segmental glomerulosclerosis was rebuffed by the FDA in 2021, and the failure of the pivotal Duplex trial this week suggests that the agency was right to wait for more rigorous results. Not that the company is giving up on getting the drug to market in this use, with talks planned with regulators about potential ways forward.